Fibrolamellar Cancer Foundation

Analysis

Fibrolamellar Cancer Foundation is a registered charity in United States, based in Greenwich, CT. It received its IRS tax-exemption ruling in August 2010, 16 years ago. Its declared purposes cover diseases, disorders and medical disciplines, which this site groups under health and saving lives. The IRS classifies it as a publicly supported organisation (donations from the general public) under section 501(c)(3), and contributions to it are listed as tax-deductible.

In the financial year ending December 2023, Fibrolamellar Cancer Foundation reported income of $3.0m and spending of $5.5m, spending 185% of what it took in. Across the 5 years on record, from December 2019 to December 2023, income grew from $1.8m to $3.0m (+67%), an average of +14% a year. The sharpest change came in the year to December 2021, when income rose by 119%. Over the whole period it spent 86% of the income it received.

Among 40,470 United States charities whose main cause is health and saving lives and that reported income, Fibrolamellar Cancer Foundation sits at the 75th percentile: it is larger than about 75% of them. Against every charity in United States with reported income it ranks in the 89th percentile, and in the 87th percentile within CT. Charities of a similar size with the same main cause include Bath Community Hospital Foundation ($3.0m), South East Shelby County Emergency Medical Rescue Inc ($3.0m) and Shared Services Home Health Care Corporation ($3.0m).

On its Form 990 for the period ending December 2023, revenue came from contributions and grants 76% of the total. Compensation of current officers, directors and key employees was $273k (5.0% of expenses). Other salaries and wages came to $365k. At year end it held assets of $10.5m against liabilities of $4.1m, net assets of $6.4m. It reported 5 employees.